Cosio Terenzio, Costanza Gaetana, Coniglione Filadelfo, Romeo Alice, Iacovelli Federico, Diluvio Laura, Dika Emi, Shumak Ruslana Gaeta, Rossi Piero, Bianchi Luca, Falconi Mattia, Campione Elena
Post Graduate School of Microbiology, Immunology, Infectious Diseases, and Transplants (MIMIT), Microbiology Section, Department of Experimental Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Dermatologic Unit, Department of Systems Medicine, University of Rome Tor Vergata, 00133 Rome, Italy.
Life (Basel). 2023 Aug 21;13(8):1781. doi: 10.3390/life13081781.
(1) Objective: Keloid and hypertrophic scars are a challenge in clinical management, causing functional and psychological discomfort. These pathological scars are caused by a proliferation of dermal tissue following skin injury. The TGF-β/Smad signal pathway in the fibroblasts and myofibroblasts is involved in the scarring process of skin fibrosis. Today, multiple therapeutic strategies that target the TGF-β/Smad signal pathway are evaluated to attenuate aberrant skin scars that are sometimes difficult to manage. We performed a head-to-head, randomized controlled trial evaluating the appearance of the post-surgical scars of 64 subjects after two times daily topical application to compare the effect of a class I pullulan-based medical device containing extract 5% and hyaluronic acid 5% gel versus a class I medical device silicone gel on new post-surgical wounds. (2) Methods: Objective scar assessment using the Vancouver Scar Scale (VSS), POSAS, and other scales were performed after 4, 8, and 12 weeks of treatment and statistical analyses were performed. The trial was registered in clinicalTrials.gov ( NCT05412745). In parallel, molecular docking simulations have been performed to investigate the role of in TGF-β/Smad signal pathway. (3) Results: We showed that VSS, POSAS scale, itching, and redness reduced significantly at week 4 and 8 in the subjects using devices containing and HA. No statistically significant differences in evaluated scores were noted at 12 weeks of treatment. Safety was also evaluated by gathering adverse events related to the application of the gel. Subject compliance and safety with the assigned gel were similar between the two study groups. Molecular docking simulations have shown how could inhibit fibroblasts proliferation and contraction via TGF-β/Smad signal pathway. (4) Conclusions: The topical application of a pullulan-based medical device containing and HA showed a clear reduction in the local inflammation, which might lead to a reduced probability of developing hypertrophic scars or keloids.
(1)目的:瘢痕疙瘩和增生性瘢痕是临床治疗中的一大挑战,会导致功能和心理上的不适。这些病理性瘢痕是皮肤损伤后真皮组织增生所致。成纤维细胞和肌成纤维细胞中的转化生长因子-β/信号转导和转录激活因子(TGF-β/Smad)信号通路参与皮肤纤维化的瘢痕形成过程。如今,人们正在评估多种针对TGF-β/Smad信号通路的治疗策略,以减轻有时难以处理的异常皮肤瘢痕。我们进行了一项直接比较的随机对照试验,评估64名受试者每日两次局部应用后手术瘢痕的外观,以比较含5%提取物和透明质酸5%凝胶的I类基于普鲁兰多糖的医疗器械与I类医疗器械硅胶对新手术后伤口的效果。(2)方法:在治疗4、8和12周后,使用温哥华瘢痕量表(VSS)、患者和观察者瘢痕评估量表(POSAS)及其他量表进行客观瘢痕评估,并进行统计分析。该试验已在ClinicalTrials.gov(NCT05412745)注册。同时,进行了分子对接模拟,以研究提取物在TGF-β/Smad信号通路中的作用。(3)结果:我们发现,使用含提取物和透明质酸的器械的受试者在第4周和第8周时,VSS、POSAS量表评分、瘙痒和发红情况均显著降低。在治疗12周时,评估分数无统计学显著差异。还通过收集与凝胶应用相关的不良事件来评估安全性。两个研究组在受试者对指定凝胶的依从性和安全性方面相似。分子对接模拟表明提取物如何通过TGF-β/Smad信号通路抑制成纤维细胞的增殖和收缩。(4)结论:局部应用含提取物和透明质酸的基于普鲁兰多糖的医疗器械可明显减轻局部炎症,这可能会降低形成增生性瘢痕或瘢痕疙瘩的可能性。